Strong Performance Yet... 3 Trillion Won Vanished in Market Cap Due to BD Acquisition and Guidance

Waters Corporation (NASDAQ: WAT), a U.S. life-sciences equipment maker, closed at $328.14 on the New York Stock Exchange on February 9, down 13.85%. Volume reached 1.43 million shares—well above the average—erasing roughly $2.38 billion in market value in a single day and leaving a market cap of about $19.5 billion. Even though the company’s Q4 2025 results, announced the previous day, slightly beat consensus on both EPS and revenue, concerns over its 2026 guidance and integration risks from its $17.5 billion acquisition of Becton Dickinson’s Biosciences & Diagnostic Solutions unit appear to have driven the sell-off.

Alongside its earnings release on the 9th, Waters confirmed the completion of the BD business acquisition and issued 2026 outlooks—including the acquired assets—of $6.405 billion to $6.455 billion in revenue and $14.30 to $14.50 in adjusted EPS. By conservatively projecting just 2.5% growth for the acquired segment in 2026 and warning of initial margin pressures and integration costs, the company triggered what analysts are calling a “guidance shock,” sending the stock sharply lower despite the earnings beat.

Founded in 1958 and headquartered in Milford, Massachusetts, Waters is an S&P 500 life-sciences firm that supplies analytical instruments—such as liquid chromatography, mass spectrometry systems and laboratory software—used in pharmaceuticals, biotech, food safety and environmental testing. With the addition of BD’s diagnostic solutions and biosciences portfolio, Waters estimates its addressable market will double. Going forward, the success of integration and the realization of synergies are expected to be key catalysts for a rebound in the share price.